# Abnormalities in the Endocannabinoid System Linked to Female Reproductive Disorders > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-female-reproductive-disorders/ > **Published:** 2021-04-06T14:26:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:11-04:00 > **Clinical Summary:** Explore how the endocannabinoid system female reproductive disorders link reveals potential therapies for conditions like endometriosis and miscarriage. --- ### The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders ​In Summary The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) (ECS) consists of cannabinoids produced naturally by the body – mainly anandamide (AEA) and 2-arachidonoylglycerol (2-AG), the [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) that they interact with – CB1 and CB2, and enzymes that synthesize and degrades them. In recent years, the importance of the ECS in both normal functions and diseases of the female reproductive system, including the endometrium and the placenta, has come into focus, owing to both laboratory research and clinical observations. In particular, the level of AEA was found to increase significantly in the blood of patients with endometriosis and miscarriage, in the fallopian tube of women with ectopic pregnancy and in endometrial biopsies of endometrial tumor. Moreover, the expression pattern of the cannabinoid receptor CB1 was demonstrated to be abnormal in endometrial biopsies of endometriosis, in fallopian tube and decidua of patients with ectopic pregnancy, and in preeclamptic placenta. Finally, alterations in CB2 expression patterns in endometrial tissues have been reported to be associated with endometrial cancer. In short, abnormalities in the ECS have been consistently linked to common female reproductive disorders including endometriosis, ectopic pregnancy, miscarriage, pre-eclampsia and endometrial cancer. For this reason, drugs that target the ECS may serve as promising new therapies for patients suffering from these diseases.​ [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Neurological and neurodegenerative conditions, physical activities, and the endocannabinoid system – how might all these be linked?](https://cedclinic.com/endocannabinoid-system-neurological-disorders-link/) Explore the broader role of the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in [neurological health](https://cedclinic.com/benzodiazepine-discontinuation-rates-medical-cannabis/) and physical activity, providing context for its systemic importance. [Read More](https://cedclinic.com/endocannabinoid-system-neurological-disorders-link/) [Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints](https://cedclinic.com/faah-inhibition-arthritis-pain-endocannabinoid-relief/) Learn about how targeting the endocannabinoid system can reduce inflammation and pain, highlighting therapeutic potentials. [Discover Insights](https://cedclinic.com/faah-inhibition-arthritis-pain-endocannabinoid-relief/) [Cannabinoids as promising anti-tumor drugs in prostate cancer](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/) Review emerging research on cannabinoids as potential anti-tumor agents, expanding understanding of ECS in cancer therapy. [Explore Research](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Abnormalities%20in%20the%20Endocannabinoid%20System%20Linked%20to%20Female%20Reproductive%20Disorders&url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-female-reproductive-disorders%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-female-reproductive-disorders%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Abnormalities%20in%20the%20Endocannabinoid%20System%20Linked%20to%20Female%20Reproductive%20Disorders%20https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-female-reproductive-disorders%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).